AVRO News and Press, AVROBIO Inc. From 09/06/19

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...

Avrobio (AVRO) recently reported impressive data for its gene therapy in Fabry's disease (see the table below). Fabry’s disease o verview Fabry’s disease is the most common lysosomal storage disease. It is an X-linked inborn error due to mutations in the alpha-Gal-A ge...

AVROBIO, Inc . (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences. Citi’s 14th Annual Biotech Conference Date: Wednesday, September 4, 2019 L...

AVROBIO, Inc . (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the appointment of Georgette Verdin as Chief Human Resources Officer (CHRO). Ms. Verdin will be responsible for all aspects of human resource...

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...

AVROBIO, Inc. (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2018 Stock Option ...

AVROBIO (NASDAQ: AVRO ): Q2 GAAP EPS of -$0.67 beats by $0.09 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Reported positive interim results from clinical trials of AVR-RD-01 investigational gene therapy in Fabry disease, including 87% substrate reduction in first kidney biopsy at one year post-treatment On track to dose first patients in Phase 1/2 clinical trials for Gaucher and cystinosis...

AVROBIO, Inc . (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 2:30 p.m. ET at the Parker New York Hotel in New York City. Geoff MacKay, AVROBIO...

Gainers: PRCP   +12.2% . PHM   +1.8% . AVRO   +1.5% . More news on: Perceptron, Inc., PulteGroup, Inc., AVROBIO, Inc., Stocks on the move, Read more ...